FARMERS & MERCHANTS TRUST Co OF LONG BEACH Sells 535 Shares of Johnson & Johnson (NYSE:JNJ)

FARMERS & MERCHANTS TRUST Co OF LONG BEACH lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 28,544 shares of the company’s stock after selling 535 shares during the period. Johnson & Johnson accounts for 1.0% of FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s portfolio, making the stock its 23rd largest position. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Johnson & Johnson were worth $4,128,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dominguez Wealth Management Solutions Inc. grew its position in shares of Johnson & Johnson by 1.1% during the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 23,707 shares of the company’s stock worth $3,429,000 after buying an additional 261 shares during the period. Canoe Financial LP grew its holdings in Johnson & Johnson by 3.2% during the fourth quarter. Canoe Financial LP now owns 92,626 shares of the company’s stock valued at $13,396,000 after purchasing an additional 2,900 shares during the period. Retirement Wealth Solutions LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at approximately $73,000. Brooklyn Investment Group raised its holdings in Johnson & Johnson by 33.2% in the fourth quarter. Brooklyn Investment Group now owns 16,457 shares of the company’s stock worth $2,380,000 after purchasing an additional 4,099 shares during the period. Finally, Defined Wealth Management LLC boosted its position in shares of Johnson & Johnson by 3.8% during the fourth quarter. Defined Wealth Management LLC now owns 3,063 shares of the company’s stock worth $443,000 after purchasing an additional 111 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $147.03 on Monday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company’s 50-day moving average is $148.51 and its 200 day moving average is $156.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.37%. Johnson & Johnson’s payout ratio is 71.78%.

Analyst Upgrades and Downgrades

Several analysts recently commented on JNJ shares. Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim upped their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.29.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.